Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Individual aseismic areas move as rigid plates on the surface of a sphere. Application of the Mercator projection to slip vectors shows that the paving stone theory of world tectonics is correct and ...

Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...

Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on December 19, 2025, according to a report published in TheFly. On December 17, 2025, JPMorgan ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

LoL's ARAM Mayhem mode is getting some significant updates in the 26.03 PBE, with new progession meta progress, new augments, and sets too.

Hi! If you’re finding value in our Applied AI newsletter, I encourage you to consider subscribing to The Information. It ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Additionally, Recursion plans to present updated clinical data from the TUPELO trial during a webinar scheduled for December 8, 2025. This presentation will provide further insights into the safety ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...